Literature DB >> 23598817

Evolving definitions of remission in Crohn's disease.

Remo Panaccione1, Jean-Frédéric Colombel, Edouard Louis, Laurent Peyrin-Biroulet, William J Sandborn.   

Abstract

BACKGROUND: Using clinical symptoms alone to inform treatment decisions in Crohn's disease (CD) may increase the risk of disease progression and complications. Treatment beyond symptoms may offer improved outcomes.
METHODS: We explore alternative definitions of remission, beyond traditional clinical remission, incorporating more objective parameters of inflammation control, which may support prevention or delay the disease progression. These definitions could serve as a platform for future clinical research, evaluating whether treating beyond symptoms alters the natural history of CD.
RESULTS: Proposed definitions may include endoscopic remission (mucosal healing), normalization of serologic or fecal markers of inflammation, and even radiographic remission, in addition to clinical remission (symptom control). Endoscopic remission is the leading candidate for inclusion because it is the best studied. The definition should include considerations for both early and late disease given that in late disease, which may be associated with operation-related symptoms or irreversible bowel damage, symptomatic remission may not achievable. Desired outcomes in early disease are complete absence of symptoms, no disease progression, no complications or disability, and normal quality of life. In late disease, there are stabilization of noninflammatory symptoms, no progression of damage or disability, and improved quality of life.
CONCLUSIONS: Over time, we anticipate that a working definition of remission that includes both biological remission and clinical remission will evolve and be evaluated in clinical trials. Our proposed definition is a possible starting point for that evolution. Ultimately, the goal in evolving the definition of remission is to improve the outcomes in patients with CD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23598817     DOI: 10.1097/MIB.0b013e318283a4b3

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease.

Authors:  K T Park; Wallace V Crandall; Jacqueline Fridge; Ian H Leibowitz; Marc Tsou; Dana M H Dykes; Edward J Hoffenberg; Michael D Kappelman; Richard B Colletti
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

2.  Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.

Authors:  Phillip Minar; Yael Haberman; Ingrid Jurickova; Ting Wen; Marc E Rothenberg; Mi-Ok Kim; Shehzad A Saeed; Robert N Baldassano; Michael Stephens; James Markowitz; Joel Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Anne M Griffiths; Susan S Baker; Jeffrey S Hyams; Subra Kugathasan; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

3.  Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease.

Authors:  Parakkal Deepak; Joel G Fletcher; Jeff L Fidler; John M Barlow; Shannon P Sheedy; Amy B Kolbe; William S Harmsen; Edward V Loftus; Stephanie L Hansel; Brenda D Becker; David H Bruining
Journal:  Am J Gastroenterol       Date:  2016-05-10       Impact factor: 10.864

4.  Symptom clusters in adults with inflammatory bowel disease.

Authors:  Samantha Conley; Deborah D Proctor; Sangchoon Jeon; Robert S Sandler; Nancy S Redeker
Journal:  Res Nurs Health       Date:  2017-08-17       Impact factor: 2.228

Review 5.  Use of Imaging Techniques in Inflammatory Bowel Diseases That Minimize Radiation Exposure.

Authors:  Fortunata Civitelli; Emanuele Casciani; Francesca Maccioni; Salvatore Oliva; Naiwa Al Ansari; Valeria Bonocore; Salvatore Cucchiara
Journal:  Curr Gastroenterol Rep       Date:  2015-07

Review 6.  Maneuvering Clinical Pathways for Crohn's Disease.

Authors:  Thomas X Lu; Russell D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2019-04-23

Review 7.  Update on the Medical Management of Crohn's Disease.

Authors:  Parakkal Deepak; David H Bruining
Journal:  Curr Gastroenterol Rep       Date:  2015-11

8.  Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin.

Authors:  Ira Shafran; Patricia Burgunder; David Wei; Hayley E Young; Gerald Klein; Bruce P Burnett
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

9.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Authors:  Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

10.  Detailed Multi-Dimensional Assessment of Fatigue in Inflammatory Bowel Disease.

Authors:  Kristina Aluzaite; Rashid Al-Mandhari; Hamish Osborne; Christine Ho; Merrilee Williams; Marie-Michelle Sullivan; Catherine E Hobbs; Michael Schultz
Journal:  Inflamm Intest Dis       Date:  2019-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.